{"id":"W4402543961","doi":"10.1016/s0140-6736(24)01756-2","title":"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":243,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University Health Centre","funders":"National Cancer Institute; Genentech; Eisai; Daiichi-Sankyo; Chugai Pharmaceutical; Seagen; Incyte; BeiGene; Regeneron Pharmaceuticals; National Institutes of Health; Helsinn; Merck KGaA; Gilead Sciences; Sanofi; GlaxoSmithKline; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Chemotherapy; Oncology; Stage (stratigraphy); Internal medicine; Lung cancer; Adjuvant; Neoadjuvant therapy; Placebo; Adjuvant chemotherapy; Cancer; Immunotherapy; Pathology; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001555606,0.001968335,0.003780905,0.0004082217,0.0004377858,0.001185695,0.001024394,0.002114551,0.00598792],"category_scores_gemma":[0.001643895,0.0008479959,0.002611873,0.0004198834,0.001224722,0.00126312,0.000469409,0.003982191,0.001129029],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009331778,"about_ca_system_score_gemma":0.001170234,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001308553,"about_ca_topic_score_gemma":0.002921588,"domain_scores_codex":[0.999463,0.0002648552,0.00003303317,0.0001110704,0.00003392701,0.00009404436],"domain_scores_gemma":[0.9992674,0.00025613,0.0001664433,0.00005126001,0.00003897161,0.0002198859],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9889199,0.002000373,0.0001787542,0.0005467282,0.0006298035,0.00001610729,0.00002520837,0.0001564398,0.001368876,0.00005373475,0.0003659479,0.005738119],"study_design_scores_gemma":[0.9501913,0.04760456,0.0008212427,0.00004519634,0.0004989609,0.00001787941,0.00001586767,0.0002117458,0.0001946361,0.0001000358,0.0002853569,0.00001315007],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9802166,0.01011708,0.0007462126,0.001194424,0.001409625,0.002954053,0.0009029169,0.0001434423,0.00231574],"genre_scores_gemma":[0.9836897,0.004584731,0.001442701,0.001455682,0.0005626291,0.003293931,0.0008199215,0.00003131564,0.004119273],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00598792,"threshold_uncertainty_score":0.02003157,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01784361033734386,"score_gpt":0.2925656126716955,"score_spread":0.2747220023343516,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}